BioSpace News Archive

Drug Development

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Vifor Pharma announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor therapy.

December 21, 2021
·
4 min read
MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on the significant strategic profitability improvement initiatives underway at the Company.

December 21, 2021
·
9 min read
XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease• Increased Xanthine Oxidase Expression in ADPKD Kidneys •

XORTX Therapeutics Inc. is pleased to announce the filing of a provisional patent based upon recent discoveries specific to polycystic kidney disease.

December 21, 2021
·
4 min read
Drug Development

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Clearside Biomedical, Inc. announced today positive safety results from OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector®.

December 21, 2021
·
10 min read
Business

Verdi Oncology Announces New Hires to Support Community Oncology

Verdi Oncology announced today that it has enhanced its leadership team over the latter half of the year with the additions of Bill Herman (CEO), Audrey Soskin (CFO), and Brian Battey (SVP-Strategic Growth).

December 21, 2021
·
3 min read
Drug Development

Ixtlan Bioscience Announces the Filing of New Patent for the Psilocybin Treatment of Alzheimer’s Disease and Brain Pathologies

Ixtlan Bioscience has announced today the filing of a new Provisional Patent with the United States Patent and Trademark Office (USPTO) Application No. 63279349 – named; Ixtlan AD Kit, which is a novel treatment for Alzheimer’s and neuronal disorders.

December 21, 2021
·
2 min read
Business

Vipergen Establishes Research Partnership with Bayer to Discover Novel Compoundsfor Pharmaceuticals and More Sustainable Crop Protection Solutions

Vipergen announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions.

December 21, 2021
·
3 min read
Business

CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

CytoSorbents Corporation announces the appointment of Professor Daniel Wendt , MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022.

December 21, 2021
·
8 min read
FDA

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg.

December 21, 2021
·
3 min read
Business

XVIVO accelerates their business in Brazil by signing a partnership contract with Contatti Medical

XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) By selling and distributing through Contatti Medical’s well-established network in Brazil, the XVIVO market access will increase significantly.

December 21, 2021
·
2 min read